Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 28 recruiting now early-phase tilt

Colorectal Carcinoma: early-phase trial registry

28 of 54 indexed Colorectal Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #261 of 28,707 conditions by registered trial count.

54 US clinical trials · 28 currently recruiting · #261 of 28,707 conditions by registered trial count

Colorectal Carcinoma: 54 US clinical trials tracked, 28 recruiting.

Colorectal Carcinoma is the subject of 54 registered US clinical trials on ClinicalTrials.gov, 28 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 8 of these trials.

Enrollment posture brief

Registry condition colorectal-carcinoma

OPEN 28 | RECR 52% | LATE 1 | EARLY 28 | RANK #261 | SPON 8

Nearest open-share peer: Aortic Stenosis (52% recruiting · 27 trials)

Cirrhosis53.7%Colorectal Carcinoma (this)52%Obesity, Childhood46.3%Melanoma13%Brain and Central Nervous Sy1.8%
Open-enrollment share among volume-matched conditions near Colorectal Carcinoma

Colorectal Carcinoma lists 28 open slots (52% of 54 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Colorectal Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Colorectal Carcinoma is recruiting above its size-band peers.

    28 of 54 indexed trials (51.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Colorectal Carcinoma trials is spread across many organizations.

    National Cancer Institute (NCI) accounts for 8 of 54 trials (14.8%). 32 distinct sponsors appear on at least one study for this condition label.

  3. Typical Colorectal Carcinoma enrolment sits around 124 participants.

    Median target enrolment is 124 among the 54 trials that report a genuine target (sentinel values excluded). 23 of those (42.6%) plan for fewer than 100 participants.

  4. Colorectal Carcinoma research is mostly interventional.

    47 interventional and 7 observational studies make up this index (87% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 119Phase 29Phase 31

Open and recent trials

54 total, page 1 of 2

RECRUITING NA 24,000 participants

The Vanguard Study: Testing a New Way to Screen for Cancer

National Cancer Institute (NCI)

NCT06995898

RECRUITING NA 2,200 participants

Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)

University of Kansas Medical Center

NCT06682650

RECRUITING NA 2,067 participants

The Ohio State University (OSU) SCREEN Community Program

Ohio State University Comprehensive Cancer Center

NCT06666192

RECRUITING 2,000 participants

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Wake Forest University Health Sciences

NCT06418204

RECRUITING NA 1,680 participants

Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps

Jonsson Comprehensive Cancer Center

NCT06376565

RECRUITING NA 1,500 participants

A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemical Test Result in Patients at Federally Qualified Health Centers

Jonsson Comprehensive Cancer Center

NCT06568016

RECRUITING 1,366 participants

Collection of Information to Better Understand Young Onset Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT04489238

RECRUITING 750 participants

Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients

Mayo Clinic

NCT05410977

RECRUITING NA 500 participants

Confronting Cancer as a Community

University of Southern California

NCT06063928

RECRUITING NA 450 participants

Addressing Disparities in Colorectal Cancer Screening in Black and Underserved Phoenix Communities

Mayo Clinic

NCT05447923

RECRUITING Phase 1 150 participants

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Tasca Therapeutics

NCT07030257

RECRUITING Phase 1 147 participants

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

NCT04851119

RECRUITING NA 140 participants

CoGENES Randomized Controlled Trial (RCT)

University of Southern California

NCT07229443

RECRUITING Phase 1 135 participants

A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

Boehringer Ingelheim

NCT06882746

RECRUITING Phase 1 130 participants

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Janux Therapeutics

NCT05783622

RECRUITING Phase 1 124 participants

A Study of MGC028 in Participants With Advanced Solid Tumors

MacroGenics

NCT06723236

RECRUITING 120 participants

Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT04812912

RECRUITING Phase 1 108 participants

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

AstraZeneca

NCT06218914

RECRUITING NA 85 participants

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

Barbara Ann Karmanos Cancer Institute

NCT07436078

RECRUITING NA 80 participants

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

University of Michigan Rogel Cancer Center

NCT07291414

RECRUITING NA 56 participants

A Web-Based Dyadic Intervention for Colorectal Cancer

Emory University

NCT05663203

RECRUITING Phase 1 46 participants

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

AstraZeneca

NCT05877599

RECRUITING Phase 1 36 participants

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

National Cancer Institute (NCI)

NCT05630794

RECRUITING Phase 1 30 participants

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

NCT07118176

RECRUITING 30 participants

Role of Diet on the Microbiome of the Digestive System

M.D. Anderson Cancer Center

NCT04666727

RECRUITING NA 30 participants

Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors

Fred Hutchinson Cancer Center

NCT05930496

RECRUITING Phase 2 27 participants

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Mayo Clinic

NCT07285044

RECRUITING Phase 1 24 participants

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

City of Hope Medical Center

NCT06130826

ACTIVE NOT RECRUITING NA 9,745 participants

Implementation Research to Increase Colorectal Cancer Screening Rates Among Low Income and Ethnic Minority Groups

Jonsson Comprehensive Cancer Center

NCT06090643

ACTIVE NOT RECRUITING Phase 2 6,452 participants

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

NCT02465060

ACTIVE NOT RECRUITING 818 participants

Young-Onset Colorectal Cancer

M.D. Anderson Cancer Center

NCT02863107

ACTIVE NOT RECRUITING NA 465 participants

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

City of Hope Medical Center

NCT04905082

ACTIVE NOT RECRUITING NA 261 participants

Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study

Fred Hutchinson Cancer Center

NCT04081779

ACTIVE NOT RECRUITING Phase 2 186 participants

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

National Cancer Institute (NCI)

NCT05419011

ACTIVE NOT RECRUITING NA 146 participants

Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques

M.D. Anderson Cancer Center

NCT03151564

ACTIVE NOT RECRUITING Phase 1 130 participants

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals

NCT05215574

ACTIVE NOT RECRUITING Phase 2 110 participants

Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

National Cancer Institute (NCI)

NCT02134925

ACTIVE NOT RECRUITING Phase 2 81 participants

Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma

National Cancer Institute (NCI)

NCT02965703

ACTIVE NOT RECRUITING Phase 1 74 participants

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Novartis Pharmaceuticals

NCT05358249

ACTIVE NOT RECRUITING Phase 1 45 participants

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

National Cancer Institute (NCI)

NCT05078866

ACTIVE NOT RECRUITING Phase 2 42 participants

Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis

Northwestern University

NCT04767984

ACTIVE NOT RECRUITING Phase 2 40 participants

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Seagen, a wholly owned subsidiary of Pfizer

NCT04430738

ACTIVE NOT RECRUITING Early Phase 1 27 participants

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Julie L. Sutcliffe, Ph.D

NCT03164486

ACTIVE NOT RECRUITING NA 20 participants

Community Genetic Navigation Engagement Specialists to Increase Knowledge About Colorectal Cancer Genetics in Hispanic/Latino/a Communities

University of Southern California

NCT07276048

ACTIVE NOT RECRUITING Phase 1 12 participants

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

University of California, Irvine

NCT04868773

COMPLETED Phase 3 621 participants

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults

Norgine

NCT02254486

COMPLETED NA 261 participants

Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms

University of Pittsburgh

NCT01640522

COMPLETED Phase 1 150 participants

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Xencor

NCT03517488

COMPLETED Phase 1 111 participants

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

NuCana

NCT03428958

COMPLETED Phase 1 95 participants

Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma

MacroGenics

NCT02248805

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 19
Phase 2 9
Phase 3 1

Named interventions

Most-linked intervention names on Colorectal Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Biospecimen Collection Procedure
12 trials
Questionnaire Administration Other
9 trials
Educational Intervention Other
8 trials
Interview Other
5 trials
Electronic Health Record Review Other
5 trials
Best Practice Other
5 trials
Survey Administration Other
4 trials
Biopsy Procedure Procedure
3 trials

US sites by state

Facility locations filed on Colorectal Carcinoma trials. A trial with sites in several states counts in each.

California 26 trials
Texas 14 trials
Michigan 12 trials
Pennsylvania 11 trials
New York 11 trials
Massachusetts 11 trials
Ohio 9 trials
Arizona 9 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Colorectal Carcinoma page

54 registered trials, 28 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colorectal Carcinoma condition card totals 54 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.